- Company
- Will the high-priced Hemgenix be reimbursed in Korea?
- by Whang, byung-woo Sep 23, 2024 05:50am
- The reimbursement listing process for Hemgenix (etranacogene dezaparvovec-drlb), a 'one-shot' treatment for hemophilia B that shows its effect as a single dose that received domestic approval recently, has been gaining attention in Korea. According to industry sources on the 21st, the Ministry of Food and Drug Safety (MFDS) recently appro
- Company
- Will restrictions on oral SMA drug Evrysdi be lifted?
- by Eo, Yun-Ho Sep 23, 2024 05:50am
- Whether the prescription restrictions set on the oral spinal muscular atrophy (SMA) treatment ‘Evrysdi’ may be lifted is gaining attention in Korea. According to Dailypharm coverage, Roche Korea applied to expand the reimbursement of its SMA treatment Evrysdi (risdiplam), which is currently allowed up to 2 bottles per day, and the agend
- Company
- Peter Trang will head Business Operations at Takeda Korea
- by Whang, byung-woo Sep 20, 2024 05:51am
- On the 19th, Takeda Korea announced that it appointed Peter Trang from Australia as the new Head of Business Operations. The new head joined Takeda Pharmaceuticals Australia in 2016 as Business Insights Manager, then moved on and became the Strategy Lead of the Growth & Emerging Markets Business Unit (BU), which oversaw operations in more
- Company
- Ipsen Korea appoints Yang mi-sun as new CEO
- by Eo, Yun-Ho Sep 20, 2024 05:51am
- Ipsen Korea has appointed Yang Mi-sun, AstraZeneca Korea’s former Business Unit Director, as the new Chief Executive Officer (CEO). Sources said that Ipsen Korea has appointed its new CEO, replacing former CEO Audrey Schweitzer after the end of her term. Audrey Schweitzer has been in charge of Ipsen Korea since 2021. Yang is an indust
- Company
- Inventage Lab to codevelop a long-acting injectable with BI
- by Lee, Seok-Jun Sep 20, 2024 05:51am
- Inventage Lab (CEO Ju-Hee Kim) announced on the 19th that it has signed an agreement with Boehringer Ingelheim, a German multinational pharmaceutical company, to co-develop a long-acting injectable formulation for a new peptide drug. Inventage Lab will develop a long-acting injectable formulation based on Boehringer Ingelheim's drug cand
- Company
- Samsung Bioepis recruits Lina Choi as new global head
- by Nho, Byung Chul Sep 19, 2024 05:48am
- Samsung Bioepis garners attention as the company recruits specialists to strengthen its global entry capacity. Sources said that Samsung Bioepis has recruited Linda Choi, Vice President, as the Head of Global Commercial in August. Choi studied pharmacy at Ohio State University College of Pharmacy and has 28 years of experience in mult
- Company
- Will Columvi be reviewed for reimb by CDDC in OCT?
- by Eo, Yun-Ho Sep 19, 2024 05:48am
- Demand is rising for the reimbursement of ‘Columvi,’ the first bispecific antibody treatment option for lymphoma, in Korea. The Korea Leukemia Patients Organization has requested the CD20-CD3 bispecific antibody for diffuse large B-cell lymphoma (DLBCL) Columvi (glofitamab) be redeliberated at the Health Insurance Review and Assessment
- Company
- Reimb for orphan drug 'Welireg' for cancer has been denied
- by Eo, Yun-Ho Sep 19, 2024 05:48am
- An orphan drug, 'Welireg,' for cancer still faces challenges in entering insurance reimbursement coverage. Sources said that MSD Korea is preparing to reapply for reimbursement review of its oral hypoxia-inducible factor 2 alpha (HIF-2α) inhibitor, Welireg (belzutifan), after failing to pass the Cancer Disease Review Committee (CDRC) rev
- Company
- JAK inhibitor 'Jyseleca' approved for use at 'Big 5'
- by Eo, Yun-Ho Sep 13, 2024 05:50am
- The JAK inhibitor 'Jyseleca' has been successfully introduced to general hospitals. Sources said Jyseleca, the fifth JAK inhibitor in South Korea, has passed the drug committees (DC) of 'Big 5' tertiary hospitals, including Samsung Medical Center, Seoul University Hospital, Seoul St. Mary's Hospital, Seoul Asan Medical Center, and Sincho
- Company
- Global guidelines recommend Leclaza combination therapy
- by Son, Hyung-Min Sep 13, 2024 05:49am
- Leclaza plus Rybrevant combination therapy has been listed as a first-line therapy in global guidelines after demonstrating improvements in survival rates. Leclaza plus Rybrevant combination therapy, which is the new treatment for epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), received U.S. Food and Drug A
